- Boehringer Ingelheim Canada’s Jascayd (nerandomilast) has received Health Canada authorization for adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), becoming Canada’s first authorized PDE4B inhibitor for these indications.
- The authorization is supported by Phase III FIBRONEER-IPF and FIBRONEER-ILD trials, which met their primary endpoints by demonstrating slower lung function decline, measured by forced vital capacity (FVC), versus placebo at Week 52.
- Although key secondary endpoints were not met in either trial, a numerical reduction in mortality was observed across both studies, reaching nominal significance in FIBRONEER-ILD. Nerandomilast also demonstrated a favorable safety profile without requiring liver monitoring.
- The authorization introduces a new treatment option for progressive, life-limiting lung diseases, with more than 17,000 Canadians estimated to live with IPF. Jascayd is the first IPF treatment in over a decade to demonstrate efficacy and a new PPF option in more than five years.
Takeaways:
Boehringer Ingelheim’s Jascayd authorization introduces a new mechanism into Canada’s IPF and PPF markets, potentially reshaping competition in fibrotic lung disease. Phase III evidence of slower lung function decline and no requirement for liver monitoring may support adoption, although unmet secondary endpoints and the need to demonstrate real-world benefits could influence physician uptake.
Source: CA Newswire
